泽璟制药(688266) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total revenue of RMB 53,390.87 million in 2024, representing a year-on-year increase of 38.16%[5] - The net loss attributable to the parent company was RMB -13,621.51 million, a reduction in loss of RMB 14,236.76 million compared to the previous year[5] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was RMB -16,460.65 million, with a year-on-year reduction in loss of RMB 18,413.87 million[5] - The weighted average return on net assets was -8.71%, improving by 11.29 percentage points year-on-year[5] Assets and Equity - Total assets at the end of the reporting period were RMB 300,541.70 million, an increase of 4.09% compared to the beginning of the period[5] - Equity attributable to the parent company decreased by 22.74% to RMB 126,146.14 million[4] - The net asset per share attributable to the parent company was RMB 4.77, down 22.69% year-on-year[4] Revenue Drivers and Cost Management - The increase in revenue was primarily driven by the steady promotion of Donafenib tablets and the expansion of hospital coverage for drug access[6] - The company focused on new drug research and development while managing costs effectively, leading to a reduction in various expenses[6] Financial Data Disclaimer - The company warns that the financial data presented is preliminary and subject to change upon final audit[8]